Literature DB >> 28435168

How are Interactions Taken into Account in Studies on Conventional and Complementary Therapies for Breast Cancer Patients with Menopausal Complaints?

J Hübner1, K Münstedt2, R Mücke3, O Micke4.   

Abstract

Introduction: Postmenopausal symptoms in breast cancer patients undergoing antihormone treatment lead to high drop-out rates from the therapy. From the therapeutic point of view, methods of both conventional and complementary medicine are concerned. Interactions are being discussed in cases of natural substances. However, they are also relevant for conventional medical substances. The aim of this analysis is to answer the question as to what extent potential interactions are taken into account in clinical studies and reviews on supportive therapies. Materials and
Methods: Clinical studies and reviews were identified by means of a systematic search and analysed with regard to the consideration of potential interactions.
Results: Altogether 46 clinical studies and one Cochrane review were found. Among the 35 studies on conventional drug therapies, 5 (14 %) took possible interactions into account. Among the 17 studies on complementary medicine, there were 2 (11.7 %) such publications. The Cochrane review did not mention interactions. Discussion: For future studies in which interactions cannot be excluded, a strategy to control for their clinically relevant consequences should be developed. The present authors suggest that the use of survival and recurrence data as secondary endpoints, also for studies on purely supportive therapies, is a reasonable approach. The resulting considerations for study routines are listed thematically.

Entities:  

Keywords:  antihormone therapy; breast cancer; complementary medicine; hormone withdrawal signs; interactions

Year:  2012        PMID: 28435168      PMCID: PMC5396550          DOI: 10.1055/s-0032-1327854

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  53 in total

1.  Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer.

Authors:  Janet S Carpenter; Anna Maria Storniolo; Shelley Johns; Patrick O Monahan; Faouzi Azzouz; Julie L Elam; Cynthia S Johnson; Richard C Shelton
Journal:  Oncologist       Date:  2007-01

2.  Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study.

Authors:  L Mariani; M Quattrini; M Atlante; M Galati; A Barbati; D Giannarelli
Journal:  J Exp Clin Cancer Res       Date:  2005-09

3.  Homeopathic treatment of hot flushes: a pilot study.

Authors:  A Clover; D Ratsey
Journal:  Homeopathy       Date:  2002-04       Impact factor: 1.444

4.  Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial.

Authors:  Jennifer Jacobs; Patricia Herman; Krista Heron; Steven Olsen; Lucy Vaughters
Journal:  J Altern Complement Med       Date:  2005-02       Impact factor: 2.579

5.  Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study.

Authors:  Ciska Buijs; Constantijne H Mom; Pax H B Willemse; H Marike Boezen; J Marina Maurer; A N Machteld Wymenga; Robert S de Jong; Peter Nieboer; Elisabeth G E de Vries; Marian J E Mourits
Journal:  Breast Cancer Res Treat       Date:  2008-08-01       Impact factor: 4.872

6.  Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer.

Authors:  Eini Nikander; Merja Metsä-Heikkilä; Olavi Ylikorkala; Aila Tiitinen
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

7.  Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients.

Authors:  Gary Deng; Andrew Vickers; Simon Yeung; Gabriella M D'Andrea; Han Xiao; Alexandra S Heerdt; Steven Sugarman; Tiffany Troso-Sandoval; Andrew D Seidman; Clifford A Hudis; Barrie Cassileth
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

8.  Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion.

Authors:  Janet S Carpenter; Menggang Yu; Jingwei Wu; Diane Von Ah; Jennifer Milata; Julie L Otte; Shelley Johns; Bryan Schneider; Anna Maria Storniolo; Ronald Salomon; Zeuresenay Desta; Donghua Cao; Yan Jin; Santosh Philips; Todd C Skaar
Journal:  Menopause       Date:  2009 Jul-Aug       Impact factor: 2.953

9.  Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study.

Authors:  Eugene G Lipov; Jaydeep R Joshi; Sarah Sanders; Kris Wilcox; Sergei Lipov; Hui Xie; Robert Maganini; Konstantin Slavin
Journal:  Lancet Oncol       Date:  2008-05-15       Impact factor: 41.316

10.  Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E.

Authors:  N Biglia; P Sgandurra; E Peano; D Marenco; G Moggio; V Bounous; N Tomasi Cont; R Ponzone; P Sismondi
Journal:  Climacteric       Date:  2009-08       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.